by Administrators Qynapse | Sep 16, 2020 | News
Magnetic Resonance Imaging (MRI) of the brain plays a crucial role in the clinical assessment of Multiple Sclerosis (MS). The analysis of MRI markers is a key component for the disease diagnosis – and these markers are also employed to assess the disease stage,...
by Administrators Qynapse | Sep 7, 2020 | News
Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS). With more than 2 million people affected worldwide; MS is the leading cause of non-traumatic disability in young...
by Administrators Qynapse | Aug 31, 2020 | News
The world has been facing the COVID-19 global pandemic for several months now, yet new symptoms are still being discovered. According to a recent study, 45% of patients with severe manifestations of COVID-19 experience neurological damage and neurological symptoms...
by Administrators Qynapse | Aug 6, 2020 | News
QyScore®, the FDA-cleared and CE-marked software commercialized by Qynapse, confirms its value for the rapid measurement of brain atrophy and white matter hyperintensity in a clinical routine setting. The validation study compared the performance of QyScore® with...
by Administrators Qynapse | Jul 23, 2020 | News
The Alzheimer’s Association International Conference® (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. This year’s event takes place virtually, an exciting new way of sharing research discoveries and have...
by Administrators Qynapse | Feb 3, 2020 | News
QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders PARIS, France, Feb 3. 2020 — QYNAPSE, a medical technology company,...
